Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: Synthesis, physicochemical properties, anticancer and topoisomerase i and II inhibitory activity

European Journal of Medicinal Chemistry

Volumn 69, Issue , 2013, Pages 427-438

  Abdel Aziz, Mohamed ^a   Park, So Eun ^b   Abuo Rahma, Gamal El Din A A ^a   Sayed, Mohamed A ^a   Kwon, Youngjoo ^b  

^a Minia University   (Egypt)

^b Ewha Womans University   (South Korea)

Author keywords

Anti tumor; Chalcone; Ciprofloxacin; Hybrids; Topoisomerase

Indexed keywords

7 [ 4 [ 4 ( 3 (PHENYLACRYLOYL)PHENYLCARBAMOYL)METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 YL FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 ( 2 CHLOROPHENYL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN1 Y] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 ( 2,4 DIMETHYLPHENYL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 ( 3 CHLOROPHENYL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 ( 3 NITROPHENYL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 ( 3,4 DIMETHOXYPHENYL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 ( 3,4,5 TRIMETHOXYPHENYL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 ( 4 CHLOROPHENYL)ACROLOYL)PHENYLCARBAMOYL]METHY]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACIDL; 7 [ 4 [[ 4 ( 3 ( 4 METHOXYPHENYL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [ 4 [[ 4 ( 3 (BENZO[D][1,3]DIOXOL 5 YL)ACRYLOYL)PHENYLCARBAMOYL]METHYL]PIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOXYLIC ACID DERIVATIVE; CHALCONE DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; N 4 PIPERAZINYL CIPROFLOXACIN CHALCONE HYBRID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LIPOPHILICITY; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY;

ANTI-TUMOR; CHALCONE; CIPROFLOXACIN; HYBRIDS; TOPOISOMERASE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONE; CIPROFLOXACIN; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

EID: 84884681758     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.08.040     Document Type: Article

References (40)

1. H. Koga, A. Itoh, S. Murayama, S. Suzue, and T. Irikura Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids J. Med. Chem. 23 1980 1358 1363 (Pubitemid 11164105)
2. J. Azéma, B. Guidetti, J. Dewelle, B. Le Calve, T. Mijatovic, A. Korolyov, J. Vaysse, M. Malet-Martino, R. Martino, and R. Kiss 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents Bioorg. Med. Chem. 17 2009 5396 5407
3. J.C. Wang DNA topoisomerases Annu. Rev. Biochem. 65 1996 635 692 (Pubitemid 26250622)
4. S. Matsui, W. Endo, C. Wrzosek, K. Haridas, P. Seetharamulu, F. Hausheer, and Y. Rustum Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications Eur. J. Cancer 35 1999 984 993 (Pubitemid 29277136)
5. S. Alper, T. Arpaci, E. Aki, and I. Yalcin Some new bi- and ter-benzimidazole derivatives as topoisomerase I inhibitors IL Farmaco 58 2003 497 507 (Pubitemid 36765350)
6. Y.H. Hsiang, R. Hertzberg, S. Hecht, and L.F. Liu Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J. Biol. Chem. 260 1985 14873 14878 (Pubitemid 16211028)
7. K.C. Chow, T.L. MacDonald, and W.E. Ross DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition Mol. Pharmacol. 34 1988 467 473
8. K.M. Tewey, T.C. Rowe, L. Yang, B.D. Halligan, and L.F. Liu Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226 1984 466 468 (Pubitemid 14012819)
9. S. Rajabalian, A. Foroumadi, A. Hafiee, and S. Emami Functionalized N(2-oxyiminoethyl)piperazinyl quinolones as new cytotoxic agents J. Pharm. Pharm. Sci. 10 2007 153 158
10. R. Koziel, J. Szczepanowska, A. Magalska, K. Piwocka, J. Duszynski, and K. Zablocki Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells J. Physiol. Pharmacol. 61 2010 233 239
11. T. Kloskowski, N. Gurtowska, M. Nowak, R. Joachimiak, A. Bajek, J. Olkowska, and T. Drewa The influence of ciprofloxacin on viability of A549, HepG2, A375.S2, B16 and C6 cell lines in vitro Acta Pol. Pharm. 68 2011 859 865
12. H. Thadepalli, F. Salem, S.K. Chuah, and S. Gollapudi Antitumor activity of trovafloxacin in an animal model In Vivo 19 2005 269 276 (Pubitemid 40450407)
13. J.M. Domagala, L.D. Hanna, C.L. Heifetz, M.P. Hutt, T.F. Mich, J.P. Sanchez, and M. Solomon New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay J. Med. Chem. 29 1986 394 404 (Pubitemid 16189501)
14. S.J. Won, C.T. Liu, L.T. Tsao, J.R. Weng, H.H. Ko, J.P. Wang, and C.N. Lin Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents Eur. J. Med. Chem. 40 2005 103 112
15. G. Achanta, A. Modzelewska, L. Feng, S.R. Khan, and P. Huang A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome Mol. Pharmacol. 70 2006 426 433
16. N.J. Lawrence, R.P. Patterson, L.L. Ooi, D. Cook, and S. Ducki Effects of alpha-substitutions on structure and biological activity of anticancer chalcones Bioorg. Med. Chem. Lett. 16 2006 5844 5848 (Pubitemid 44540188)
17. R.J. Anto, K. Sukumaran, G. Kuttan, M.N. Rao, V. Subbaraju, and R. Kuttan Anticancer and antioxidant activity of synthetic chalcones and related compounds Cancer Lett. 97 1995 33 37
18. S. Ducki The development of chalcones as promising anticancer agents IDrugs 10 2007 42 46 (Pubitemid 46438282)
19. C.H. Tseng, Y.L. Chen, C.Y. Hsu, T.C. Chen, C.M. Cheng, H.C. Tso, Y.J. Lu, and C.C. Tzeng Synthesis and antiproliferative evaluation of 3-phenylquinolinylchalcone derivatives against non-small cell lung cancers and breast cancers Eur. J. Med. Chem. 59 2013 274 282
20. P. Yogeeswari, D. Sriram, R. Kavya, and S. Tiwari Synthesis and in-vitro cytotoxicity evaluation of gatifloxacin Mannich bases Biomed. Pharmacother. 59 2005 501 510 (Pubitemid 41642949)
21. M.J. Nieto, F.L. Alovero, R.H. Manzo, and M.R. Mazzieri Benzenesulfonamide analogs of fluoroquinolones. Antibacterial activity and QSAR studies Eur. J. Med. Chem. 40 2005 361 369 (Pubitemid 40460298)
22. T.D. Gootz, P.R. Mcguirk, M.S. Moynihan, and S.L. Haskell Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase Antimicrob. Agents Chemother. 38 1994 130 133 (Pubitemid 24018169)
23. F.L. Alovero, X.S. Pan, J.E. Morris, R.H. Manzo, and L.M. Fisher Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase Antimicrob. Agents Chemother. 44 2000 320 325 (Pubitemid 30060726)
24. Y. Fengping, P. Yangping, S. Gonghua, and L. Jizong Solid phase synthesis of amino-chalcones J. Chem. Res. 2005 2005 311 312
25. K. Nakaya, K. Funabiki, K. Shibata, H. Muramatsu, and M.M. Matsul Fluorescent α,β-unsaturated carbonyl compounds and 2-methoxypyridines. Their application to a quantitative analysis of carnitines Bull. Chem. Soc. Jpn. 69 1996 2961 2966 (Pubitemid 26355164)
26. F.L. Ansari, S. Umbreen, L. Hussain, T. Makhmoor, S.A. Nawaz, M.A. Lodhi, S.N. Khan, F. Shaheen, M.I. Choudhary, and M.I. Atta-ur-Rahman Syntheses and biological activities of chalcone and 1,5-benzothiazepine derivatives: promising new free-radical scavengers, and esterase, urease, and alpha-glucosidase inhibitors Chem. Biodivers. 2 2005 487 496 (Pubitemid 40691591)
27. G.A. Abuo-Rahma, H.A. Sarhan, and G.F.M. Gad Design, synthesis, antibacterial activity and physicochemical parameters of novel N-4-piperazinyl derivatives of norfloxacin Bioorg. Med. Chem. 17 2009 3879 3886
28. The methodology of the NCI anticancer screening has been described in detail elsewhere http://www.dtp.nci.nih.gov
29. S.A. Rostom Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems Bioorg. Med. Chem. 14 2006 6475 6485 (Pubitemid 44233325)
30. B.A.D. Neto, and A.A.M. Lapis Recent developments in the chemistry of deoxyribonucleic acid (DNA) intercalators: principles, design, synthesis, applications and trends Molecules 14 2009 1725 1746
31. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat. Rev. Cancer 9 2009 338 350
32. J.L. Nitiss DNA topoisomerase II and its growing repertoire of biological functions Nat. Rev. Cancer 9 2009 327 337
33. J.R. Vance, and K.F. Bastow Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxy-acridone Biochem. Pharmacol. 58 1999 703 708 (Pubitemid 29296892)
34. X. Yu, G. Zipp, and G. Ray Davison The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion Pharm. Res. 11 1994 522 527 (Pubitemid 24144443)
35. D.L. Ross, and C.M. Riley Aqueous solubilities of some variously substituted quinolone antimicrobials Int. J. Pharm. 63 1990 237 250
36. S.A. Breda, A.F. Jimenez-Kairuz, R.H. Manzo, and M.E. Olivera solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives Int. J. Pharm. 371 2009 106 113
37. G.A. Abuo-Rahma, M. Abdel-Aziz, M. Mourad, and H. Farag Synthesis, anti-inflammatory activity and ulcerogenic liability of novel nitric oxide donating/chalcone hybrids Bioorg. Med. Chem. 20 2012 195 206
38. M. Fukuda, K. Nishio, F. Kanzawa, H. Ogasawara, T. Ishida, H. Arioka, K. Bojanowski, M. Oka, and N. Saijo Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells Cancer Res. 56 1996 789 793
39. D.H. Kang, J.S. Kim, M.J. Jung, E.S. Lee, Y. Jahng, Y. Kwon, and Y. Na New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor Bioorg. Med. Chem. Lett. 18 2008 1520 1524 (Pubitemid 351227458)
40. J.L. Vazquez, S. Merino, O. Domeinech, M. Berlanga, M. Vinas, M.T. Montero, and J. Hernandez-Borrell Determination of the partition coefficients of a homologous series of ciprofloxacin: influence of the N-4 piperazinyl alkylation on the antimicrobial activity Int. J. Pharm. 220 2001 53 62 (Pubitemid 32476841)